List of abbreviations HIV

List of abbreviations

AIDS- Acquired Immuno Deficiency Syndrome
ANC - Antenatal Cases
ART -C- Anti Retroviral Therapy Centre

BSS - Behavioral Surveillance Survey
CCC - Community Care Centre
CBO - Community Based Organization
DIC - Drop – In- Centre
DLN District Level Network
FBO - Faith Based Organization
FGD - Focus Group Discussion
FSW - Female Sex Worker
ICTC - Integrated Counseling and Testing Centre
KNP+ - Karnataka Network of Positive People
KSAPS - Karnataka State AIDS Prevention Society
LSE - Life Skills Education
LSC - Legal Services Centers
MSM Men having Sex with Men
NGO - Non Governmental Organization
NACP - National AIDS Control Programme
NACO - National AIDS Control Organization
OVC - Orphan and Vulnerable Children
OI - Opportunistic Infection
PHC - Primary Health Centre
PLHIV - People Living with HIV/AIDS
PPP - Public – Private - Partnership
STI - Sexually Transmitted Infection
TI - Targetted Intervention
TOT - Training of Trainers
TG - Transgender
TB - Tuberculosis
VH and SC - Village Health and Sanitation Committee

aids vaccine...

 International Aids Vaccine


International Aids Vaccine Initiative has now roped India into its global research network aiming to find an efficient vaccine against Aids, which infects one million people worldwide and kills more than 1,50,000 Indians.

A Rs 40-crore research centre set up jointly by IAVI and Transnational Health Sciences and Technology Institute under the department of biotechnology would start full-scale operations in another six months to study new strategies and design novel vaccine candidates.

“Vaccine is a preferred long term goal because for every two persons put on HIV treatment, five more become newly infected. Close to 46 per cent of HIV infected people in low and middle income countries do not have access to HIV medicine,”said Margaret McGlynn, president and CEO of IAVI.

The Indian laboratory comes after close to 100 Aids vaccine candidates worldwide failed to meet expectations in the last two decades, leaving the world with no Aids  vaccine despite early promises.

Out of 100 Aids vaccine candidates, only four went to large scale efficacy trial stage.

As many as 70 have been abandoned while 26 candidates are in trials, said Wayne Koff, chief scientific officer at IAVI.

Out of the remaining four candidates, two did not give desired results whereas trials on the remaining two are yet to be completed.

“All failures can be attributed to high level of variability in the human immunodeficiency virus. The outer protein in virus’s envelop in India differs by 25 per cent with that of the virus found in the USA. Because of the variability, it is difficult to make a vaccine against HIV,” Koff explained.

There is 10 per cent difference in structure and composition of envelop protein even in the HIV sub-type C found in India and South Africa.

Keeping the variability in mind, the new laboratory will focus on new strategies to develop a vaccine targeting those areas in HIV’s envelop which are conserved across strains.

“We hope to get going in a year as we are still in the stage of building the new centre. Though it will start functioning in another six months from a rented site, the centre will move to its final destination in the TSHTI in Faridabad in another two years,” said Sudhanshu Vrati, dean of TSHTI.
Source:- http://www.deccanherald.com/content/271688/aids-research-institute-come-up.html

hiv new drug from cipla

Cipla launches four in one drug for HIV patients

DIVYA RAJAGOPAL, ET Bureau Aug 14, 2012, 07.10PM IST

Tags:

• HIV|
• Cipla

MUMBAI: India's second largest drug company Cipla has launched Qvir, a combination of four HIV drugs in one single strip that would be used for a single day's treatment. The four drug kit contains Tenofovir and Emtricitabine and Atazanavir and Ritonavir. These drugs will be used for both first and second line treatment of HIV AIDS.
Cipla said by the end of 2010 close to 34 million people were living with HIV and that same year saw 2.7 million patients getting infected by the disease. "Every year about 5-10% of patients fail their first line treatment due to various reasons such as missing doses and the virus developing resistance", said Cipla